Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angiotech receives termination notice from Rex
In the notice, Rex has alleged that Angiotech materially breached its obligations under the agreement, and stated that the agreement will be terminated automatically on 24 April 2011.
In the notice, Rex has alleged that Angiotech materially breached its obligations under the agreement, and stated that the agreement will be terminated automatically on 24 April 2011.
Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs. QPS president
Net income was $377,000 for the first quarter 2010, or $0.02 loss per diluted share, compared to $1.92m, or $0.11 per diluted share, for the comparable period in
Inviragen is a developer of vaccines to protect against infectious diseases worldwide. The MOU calls for the formation of a management committee co-chaired by Casey and Dan Stinchcomb,
In the initial study with SinoFresh Homeopathic Antiseptic Nasal Spray, SinoFresh HealthCare expects to assess symptom relief for chronic sinusitis sufferers. SinoFresh is planning to conduct the trials
Earlier, Takeda collaborated with its wholly-owned subsidiaries Takeda San Francisco, Millennium Pharmaceuticals, Takeda Bio Development Center and Chemistry, Manufacturing and Controls (CMC) Center to commercialize new drug candidate
The study will evaluate ANA598, the company’s direct-acting antiviral, in both treatment-naive patients and patients who have failed a prior course of HCV therapy with interferon and ribavirin.
The randomized, controlled study will compare the use of Tryton stent in the side branch and a standard drug eluting stent in the main vessel versus angioplasty in
Following the termination of the pact, Anapharm Europe’s majority shareholder Maria Cruz Caturla has acquired PharmaNet’s minority ownership interest, and now he is the sole owner of the
Jiangchuan macrolide facility holds both macrolide API production license from China’s State Food and Drug Administration (SFDA) and related business licenses from the Industry and Commerce Bureau and